The Renin-Angiotensin System and Advanced Glycation End-Products in Diabetic Retinopathy: Impacts and Synergies.

E-ISSN： 2212-3938|8|4|285-296

ISSN： 1574-8847

Source： Current Clinical Pharmacology, Vol.8, Iss.4, 2013-11, pp. : 285-296

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Advanced Glycation End Products (AGEs) and their Receptor (RAGE) System in Diabetic Retinopathy

Current Drug Discovery Technologies, Vol. 3, Iss. 1, 2006-03 ,pp. : 83-88

Bentham Science Publishers

Access to resources Recommend Favorite

Advanced Glycation End Products and Diabetic Retinopathy

Current Medicinal Chemistry, Vol. 20, Iss. 26, 2013-09 ,pp. : 3234-3240

Bentham Science Publishers

Access to resources Recommend Favorite

Advanced Glycation End Products (AGEs), Oxidative Stress and Diabetic Retinopathy

Current Pharmaceutical Biotechnology, Vol. 12, Iss. 3, 2011-03 ,pp. : 362-368

Bentham Science Publishers

Access to resources Recommend Favorite

Role of Advanced Glycation End Products (AGEs) and Oxidative Stress in Diabetic Retinopathy

Current Pharmaceutical Design, Vol. 14, Iss. 10, 2008-04 ,pp. : 962-968

Bentham Science Publishers

Access to resources Recommend Favorite

The Therapeutic Implications of Renin-Angiotensin System Blockade in Diabetic Retinopathy

Current Pharmaceutical Biotechnology, Vol. 12, Iss. 3, 2011-01 ,pp. : 392-395

Bentham Science Publishers

Access to resources Recommend Favorite